Janssen Biotech licenses ImmuNext's VISTA therapeutics; ImmuNext regains rights to CI8993
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive global development and commercialization rights to ImmuNext Inc.’s (oncology and immunology therapeutics) preclinical cancer immunotherapies, which antagonize the VISTA (V-region immunoglobulin-containing suppressor of T-cell activation) signaling pathway.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.